MMM — 3M Company
Price when we picked it (Aug 31, 2026)
$173.50
Target: $185.57 (+7%)
P/E Ratio
30.6
P/E Forward
17.6
Dividend
1.8%
Market Cap
$88.7B
EPS
$5.63
Consensus
Buy
What they do
3M Company (Saint Paul, Minnesota; ~60,500 employees; CEO Bill Brown, ex-L3Harris) is America's most prolific industrial conglomerate: ~60,000 products in 200+ countries across three segments — Safety & Industrial (tapes, abrasives, N95 respirators, electrical), Transportation & Electronics (automotive adhesives, optical films for displays, aerospace) and Consumer (Scotch, Post-it, Filtrete, Command).
This position's story is the turnaround: Brown arrived in May 2024 with the playbook that multiplied L3Harris — reviving the innovation machine (92 new products in the second quarter alone, +44%; targeting ~350 in 2026 and 1,000 cumulative through 2027, with a $3.5 billion R&D plan for 2025-2027), operational discipline (on-time delivery >90%) and cleaning up the past: the Solventum (healthcare) spinoff completed in 2024 with ~15% still to monetize (~$2 billion); the earplug settlement ($6 billion) more than half paid; the public-water PFAS settlement (up to ~$12.5 billion) paying through 2036.
Our first buy was in April, two days after the first quarter that proved the inflection; the second quarter confirmed it and the stock hit an all-time high in August.
Why we like it
Three reasons to add.
- THE TURNAROUND IS NOW A TREND, NOT A QUARTER: after the first quarter we bought in April, the second (July 21) beat again — organic +5.4%, adjusted earnings $2.40 (+11%, ~7% above consensus), margin 24.9% (+40 bp) — and 2026 guidance was RAISED to $8.80–8.95 (+9-11%) with 70-80 bp of margin expansion. Two straight quarters of the same movie.
- THE INVENTION MACHINE IS BACK: 92 new products in the quarter (+44%) after 84 in the first; with $3.5 billion of R&D for 2025-2027 the 1,000-products-by-2027 goal is on track — and that's future margin, because new products sell for more.
- THE PAST SHRINKS EVERY QUARTER: earplugs more than half paid (payments left through 2029), public-water PFAS scheduled through 2036, New Jersey court-approved, and ~$2 billion of Solventum left to monetize; meanwhile it returned $1.4 billion in the quarter and the dividend has been raised twice since the cut (1.8%; 2.1% on our April cost). We're adding +19% higher, ~5% below its all-time high.
Key Risk
#1: the litigation tail isn't over. PFAS pays through 2036 (and New Jersey's payments reach the 2050s), earplugs through 2029, and in July New York's attorney general sued over PFAS — Michigan and Vermont pending: the liability shrinks but new mail keeps arriving. Others:
- a turnaround-achieved valuation: ~31x TTM earnings and ~19.5x the raised guidance, near all-time highs — one consensus aggregate has it at Hold with a $177 target (barely above the price); the margin for error narrowed;
- tariffs and the cycle: ~$110 million of tariff hit absorbed in the second quarter alone, and ~60% of revenue correlates with global manufacturing — an industrial recession hits directly;
- still-modest growth: >3.5% organic guided — the thesis is margin and innovation, not volume;
- we're buying +19% more expensive than in April: the discount is gone, we're paying for execution.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked MMM on Apr 23, 2026 at $145.48.
Full Research
3M Company (MMM) — Full Research
Price at first purchase (April 23, 2026): $145.48 | P/E TTM: 21.33 | P/E Forward: 16.92 | Div Yield: 2.14% | Market Cap: $79.7B — see the August 2026 update at the end
What It Is
3M is the most iconic science-intensive industrial conglomerate in the US. Founded in 1902 in Two Harbors, Minnesota, as Minnesota Mining and Manufacturing Company — originally to extract and sell corundum (an abrasive stone). That failed, but while searching for alternatives, they invented the first waterproof sandpaper. That mindset — "if the plan doesn't work, invent something new with what you have" — became their culture.
Today: about 61,000 employees, over 70 plants in the US, over 80 international plants, operations in more than 200 countries, over 60,000 products marketed. HQ in Saint Paul, Minnesota.
CEO: William "Bill" Brown — since May 2024, first external CEO in about 40 years. Previously CEO of L3Harris Technologies (2018-2023), where he quadrupled the stock. Engineer (Princeton, Wharton MBA). Reputation for operational rigor, lean manufacturing, and portfolio simplification.
Post-Solventum Structure (April 2024)
| Segment | % Revenue 2025 | Key Products |
|---|---|---|
| Safety & Industrial | ~43% | Industrial Scotch tapes, abrasives, N95 respirators, PPE, sealants, electrical insulations |
| Transportation & Electronics | ~32% | Automotive adhesives, optical films (iPhone/TV/monitor screens), fiber optics, aerospace materials |
| Consumer | ~15% | Scotch, Post-it, Command, Scotch-Brite, Nexcare, Filtrete, Ace |
| Corporate/Other | ~10% | Residual revenues and unallocated costs |
Revenue FY 2025: ~$24B (post-spin). Versus pre-spin when it was ~$32B with Health Care included.
The Lost Decade (2014-2024)
Before understanding the buy thesis, it's important to understand what went wrong:
1. The Inge Thulin → Mike Roman Era (2014-2024)
Inge Thulin (CEO 2012-2018) led 3M conservatively. Mike Roman (2018-2024) maintained the course. But during that decade:
- Organic growth stalled: 2014-2023 average organic growth ~1.2% annually. Well below comparable industrials (Honeywell ~3%, Illinois Tool Works ~3%).
- Portfolio inflated: they kept adding SKUs without cutting. Operating complexity rose, margins fell.
- R&D as % revenue dropped: historically 6%+ → by 2024 it was ~4.8%. The innovation pipeline dried up.
- Poor brand management of Scotch/Post-it: consumer lines grew below inflation — lost share to Henkel in Europe and private labels in retail.
2. Litigation Avalanche
Two simultaneous legal catastrophes:
PFAS (2019-present): 3M pioneered PFAS (perfluoroalkyl substances) — the "forever chemicals". They used them in Scotchgard, tapes, firefighting foams. Since the 90s, there's evidence they cause cancer. In 2019, massive lawsuits emerged from states and water utilities. In June 2023, 3M agreed to the $12.5B settlement for US drinking water systems (final court approval in April 2024). Structured over 13 years — annual payments ~$440M in April. Separate lawsuits from individual states, personal injury suits, and European regulation continue. 3M exited PFAS manufacturing by the end of 2025 (fulfilled).
Combat Arms Earplugs (2018-2023): 3M sold earplugs (Combat Arms v2) to the US military. Veterans alleged defects causing hearing loss. More than 260,000 individual lawsuits — the largest multidistrict litigation in US history. In August 2023, 3M agreed to a $6B settlement, payable in cash + stock over 2024-2029.
Combined: ~$18.5B in liabilities, nearly three times 3M's annual earnings.
3. Solventum Spinoff (April 2024)
3M announced in July 2022 that it would spin off its Health Care segment (wound care, dental, hospital software). Completed April 1, 2024, as Solventum Corporation (NYSE: SOLV).
Reasons for the spin:
- Health Care had different market dynamics (more growth, more capital-intensive, regulated)
- Freed up capital management attention to focus on industrial
- A "pure" Health Care ticker captured a premium valuation (SOLV trades at ~25x forward vs MMM ~17x)
But the spin required cutting the dividend:
- 3M pre-spin: annual dividend ~$6.00 (yield ~5% at $120)
- Post-spin (April 2024): dividend fell to ~$2.80 (adjusted for Solventum distributed)
- Lost "Dividend King" status: 67 consecutive years of raising the dividend → truncated.
That triggered massive sales: investors who bought 3M specifically for the Dividend Aristocrat status rotated to Johnson & Johnson, PG, KO. That group won't return.
William Brown — The Turnaround (May 2024-present)
Mike Roman resigned in April 2024 right after the Solventum spin. The board did something 3M hadn't done in ~40 years: hire an external CEO.
William M. Brown was CEO of L3Harris Technologies (merged Harris + L3 in 2019). Under his leadership:
- L3Harris stock: $153 (August 2018) → $210 (April 2023) → ~4x over the S&P industrial index
- Consolidated over 60 plants into 30
- Expanded operating margin ~400 basis points
- Executed $8B in non-core divestitures
At 3M, Brown has done in 24 months what Mike Roman didn't do in 6 years:
1. Radical Portfolio Review (June 2024)
First CEO in over 30 years to conduct a full review of the 60,000+ SKUs. Result:
- ~30% of products identified as "low strategic value" or "low margin"
- Plan to rationalize 30-40% of those over 2025-2027
2. Plant Consolidation
- 2024: closed 7 plants (mainly in the US and Mexico)
- 2025: closed/sold 12 more plants
- Total target: ~25 plants closed/sold by 2027 (20% of the footprint)
3. Headcount Reductions
- September 2024: announced 6,000 global cuts
- April 2025: 2,500 more
- Total: ~8,500 reduction (~12% of the global workforce)
4. Operating Margin Recovering
- FY 2023: op margin GAAP ~16%
- FY 2024: 19.8%
- FY 2025: 21.5%
- Q1 2026: 23.2% (+230 basis points YoY)
5. R&D Reinstated
- Brown announced in Q3 2025 call that R&D will be restored to ~5.5% of revenue (vs 4.8% current)
- New labs in Austin and Singapore operating from 2026
Q1 2026 Earnings — The Pivotal Moment (April 21, 2026)
Results (2 days ago):
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| GAAP Revenue | $6.00B | $5.92B | +1.3% |
| Adj EPS | $2.14 | $1.88 | +13.8% |
| Adj Op Margin | 23.2% | 20.9% | +230 basis points |
| GAAP EPS | $1.23 | $2.05 | -40%* |
| Free Cash Flow | $1.1B | $0.9B | +22% |
*GAAP EPS fell due to one-time charges (restructuring + PFAS settlement payment)
By segment:
| Segment | Organic Growth |
|---|---|
| Safety & Industrial | +2.5% |
| Transportation & Electronics | +1.1% |
| Consumer | -1.2% |
FY 2026 Guidance Raised:
- Adj EPS: $8.50-$8.70 (prev $8.40-$8.60)
- Organic sales growth: ~3%
- Operating margin expansion: +70-80 basis points over FY 2025
The market reacted: MMM +7% on April 21, closing at $145+ after the call.
Financial Metrics
| Metric | Value |
|---|---|
| Price | $145.48 |
| Market Cap | $79.7B |
| P/E TTM | 21.33x |
| P/E Forward | 16.92x |
| EPS TTM | $6.82 |
| EPS Forward (guide midpoint) | $8.60 |
| Dividend Yield | 2.14% |
| Annual Dividend | $3.12 |
| Payout Ratio | ~46% |
| 52w High | $177.41 |
| 52w Low | $134.85 |
| Drawdown from high | -18.0% |
| Revenue FY 2025 | ~$24B |
| Adj Op Margin FY 2025 | 21.5% |
| ROE | ~28% |
| FCF LTM | ~$4.8B |
| Net Debt | ~$10B |
| Buyback authorized (Nov 2025) | $7.5B |
Why Now
1. Q1 2026 Confirmed Turning Point
+230 basis points margin expansion is not noise — it's the first sustained evidence that Brown's work is translating into numbers. The market is just starting to process.
2. Valuation vs Peers
Honeywell 24x forward, Emerson 23x, ITW 24x, Illinois Tool Works 24x. MMM at 17x forward — the cheapest pure industrial in the sub-sector with documented turnaround.
3. Legal Overhang Capped
PFAS ($12.5B) and Earplugs ($6B) are both structured. It's not total risk elimination but the "tail" is now calculable — the market can model, not fear.
4. Capital Return Restored
Dividend raised to $3.12 (first increase post-spin) + $7.5B buyback authorized = clear board signal that capacity was restored.
5. Spinoff Clarity
A pure industrial, without Health Care. Easy to analyze, easy to compare vs peers. The multiple will normalize.
6. Consumer Discretionary Recovery
If the US avoids recession in 2026, Transportation (auto OEM) and Consumer (Scotch, Post-it) segments can have a better year. Guidance assumes flat growth there — upside exists.
Risks
1. PFAS — The Long Tail
The $12.5B settlement covers US water utilities, not covered: (a) individual states (NJ, NH, MN are litigating separately); (b) personal injury (individual cancer plaintiffs); (c) European regulation (ECHA may impose new limits in 2027); (d) future federal actions. Analysts estimate additional exposure of $5-15B.
2. Industrial Cyclicality
About 60% of revenue is pro-cyclical. If global manufacturing enters a recession in 2H 2026, organic growth can return to flat. Guidance +3% assumes soft landing.
3. Internal Culture vs External CEO
William Brown is the first external CEO in over 40 years. 3M culture is dense: "15% time" (engineers dedicate 15% of time to own projects — that's how Post-it was born), average tenure ~15 years, constant internal rotation. Brown comes from top-down defense contractor culture. Cultural clashes can undermine execution.
4. Dividend Aristocrat Status Lost
67 years of increases broken in 2024. There's no way to regain that rating — the investors who buy specifically Dividend Kings (there are dedicated ETFs like NOBL) have already rotated out. The marginal buyer base now is turnaround/value, not income.
5. Competition in "Neglected" Products
While 3M spent a decade fighting lawsuits, competitors took share:
- Henkel (Germany) in industrial adhesives
- Honeywell in N95 and PPE
- Nitto Denko (Japan) in optical films
- Private labels in Consumer (Scotch copies at Target, Amazon Basics)
Regaining share takes years and money.
6. China Exposure
About 8% of revenue comes from China (it used to be ~10%). Over 10 plants in China that cannot be easily relocated. Tariffs or US-China trade tensions would directly affect.
7. R&D Gap May Persist
Brown promised to raise R&D to 5.5% revenue, but increasing engineers in Minnesota is not trivial — tight labor market. If not fulfilled, the innovation pipeline (3M's historical advantage) continues to weaken.
8. Free Cash Flow Constrained
About $440M/year in PFAS payments until 2036 + Earplugs payments + capex for transformation = ~$1B annually committed. That restricts flexibility in M&A, more aggressive buybacks, or R&D acceleration.
Conclusion
MMM at $145.48 allows you to buy:
- An iconic 123-year-old industrial with over 130,000 patents, over 60,000 SKUs, and moats in category-defining products (Scotch, Post-it, Command, N95)
- Documented turnaround: William Brown 24 months in the role, operating margin +230 basis points YoY, $8B in cost-outs identified, portfolio simplification underway
- Post-cleanup: Solventum spun off (2024), PFAS manufacturing exited (2025), settlements structured (no more catastrophic surprises)
- Reasonable valuation: 17x forward when peers are 23-24x — ~30% discount that should close with each quarter of execution
- Renewed capital return: $3.12 div (2.14% yield) + $7.5B buyback authorized = ~4-5% total shareholder return this year via capital
- Q1 2026 as catalyst: first solid quarter post-Brown, market just starting to believe
It's not a retirement-dividend (that broke in 2024). It's a margin improvement + multiple normalization thesis in a historic industrial with capped legal issues.
If your thesis is "buy a blue-chip industrial with pedigree where the turnaround is not yet priced-in," 3M post-Solventum is the most obvious option in the sector.
Research date: April 23, 2026 | Next review: Oct 2026
This is not financial advice.
Update August 31, 2026 — Repurchase (Position #161)
Entry price: $173.50 (open) | P/E TTM 30.6x | P/E forward 17.6x | Dividend 1.8% | Market cap $88.7 billion. First buy: #50 on April 23, 2026 at $145.48 (+19.3% since). All-time closing high $182.98 on August 12; 52-week range $139.34–$184.90.
Q2 2026 (July 21). Revenue $6.5 billion; adjusted organic growth +5.4%; adjusted EPS $2.40 (+11%, ~7% above the ~$2.24 consensus); adjusted operating margin 24.9% (+40 bp); adjusted free cash flow $1.3 billion; $1.4 billion returned to shareholders in the quarter. 2026 guidance RAISED: adjusted EPS $8.80–8.95 (+9-11%, from $8.50–8.70); organic >3.5%; margin expansion 70–80 bp.
Bill Brown's turnaround. 92 new products launched in the quarter (+44%) after 84 in the first (+35%); targeting ~350 in 2026 and 1,000 cumulative through 2027; a $3.5 billion R&D plan for 2025–2027; on-time delivery >90% and OEE gains behind the margin expansion.
Litigation. Earplugs ($6 billion): more than half paid (~$3.04 billion), MDL dismissed, ~$800 million due September 15, 2026, payments through 2029. Public-water PFAS (up to ~$10.3–12.5 billion): payments through 2036; New Jersey's settlement (up to $450 million) court-approved in August. New tail: New York AG's PFAS lawsuit (July 2026); Michigan and Vermont pending.
Solventum. Sold 8.8 million shares (~$648 million) in August 2025; still holds ~15% of SOLV (~$2 billion per the 10-Q); monetization required by 2029.
Dividend and buybacks. Cut to $0.70 quarterly after the spinoff (2024), raised twice since: $0.73 (Feb 2025) and $0.78 (Feb 2026) → $3.12 a year, ~1.8% (2.1% on our April cost). Buybacks: ~$3 billion in the first half ($7.5 billion authorization).
Analysts. Consensus split by provider: StockAnalysis Buy with a $185.57 target; a MarketBeat-style tally Hold at $177.21; Barclays raised to $180.
Current risks. PFAS tail (payments to 2036; NJ into the 2050s; new state suits); valuation near highs (~31x TTM / ~19.5x guidance); tariffs (~$110 million absorbed in the quarter) and the industrial cycle; organic growth >3.5% — a margin thesis, not volume.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.